BioSpace News Archive

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced results from new analyses of the Phase 3 MAESTRO-NASH trial of Rezdiffra being presented at the EASL Congress, which takes place from June 5-8, 2024 in Milan, Italy.

Ocuphire Pharma, Inc. today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah.

AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial.

Angels for Change, a global non-profit on a mission to end drug shortages, presented the organization’s 2024 Drug Shortage Guardian Award to Fresenius Kabi USA, a health care company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.

Twist Bioscience Corporation today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy.

Melt Pharmaceuticals, Inc. today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

PARIS, FRANCE, 06 June 2024 - Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August 19, 2024.

Leading healthcare companies have joined forces to break barriers for LGBTQIA+ inclusion.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.